BBI - Brickell Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6300
+0.0700 (+4.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.5600
Open1.5800
Bid1.5000 x 800
Ask1.6800 x 800
Day's Range1.5400 - 1.7298
52 Week Range1.2200 - 8.9600
Volume242,062
Avg. Volume104,248
Market Cap12.731M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.1670
Earnings DateNov. 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.80
  • GlobeNewswire

    Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

    Brickell Biotech, Inc. (“Brickell”) (BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its development partner, Kaken Pharmaceutical Co. Ltd. (“Kaken”) submitted a new drug application for approval of manufacturing and marketing for sofpironium bromide in Japan for primary axillary hyperhidrosis. The application for sofpironium bromide in Japan involves data from the Phase 3 study in Japan, targeting patients with primary axillary hyperhidrosis, in which positive results were obtained.

  • GlobeNewswire

    Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    BOULDER, Colo., Nov. 13, 2019 -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated.

  • GlobeNewswire

    Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest

    Brickell Biotech, Inc. (“Brickell”) (NASDAQ: BBI), a clinical-stage pharmaceutical company, today announced that it has initiated an arbitration proceeding pursuant to Article 9 of the License Agreement previously entered into between Bodor Laboratories, Inc. (“Bodor”), Nicholas S. Bodor and Brickell with the American Arbitration Association (“AAA”) in Florida against Bodor and Nicholas S. Bodor. This arbitration seeks a declaratory judgment that the purported termination of the License Agreement by Bodor and Nicholas S. Bodor was invalid and unenforceable and asserts (i) a claim for breach of the License Agreement against Bodor and Nicholas S. Bodor, in his individual capacity, and (ii) a claim against Bodor and Nicholas S. Bodor for tortious interference with Brickell’s business relations.

  • GlobeNewswire

    Brickell Biotech Completes Merger with Vical

    Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company, today announced the completion of its merger with Vical Incorporated (“Vical”), following approval by Vical’s stockholders.